{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:16:19Z","timestamp":1762521379895},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1016\/j.leukres.2010.09.027","type":"journal-article","created":{"date-parts":[[2010,11,3]],"date-time":"2010-11-03T08:12:51Z","timestamp":1288771971000},"page":"380-386","source":"Crossref","is-referenced-by-count":52,"title":["Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo"],"prefix":"10.1016","volume":"35","author":[{"given":"Zhengzi","family":"Qian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luhong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huaqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2010.09.027_bib0005","doi-asserted-by":"crossref","unstructured":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89:3909\u201318","DOI":"10.1182\/blood.V89.11.3909"},{"key":"10.1016\/j.leukres.2010.09.027_bib0010","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/(SICI)1097-0142(19980201)82:3<567::AID-CNCR20>3.0.CO;2-Z","article-title":"Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors","volume":"82","author":"Bosch","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2010.09.027_bib0015","first-page":"115","article-title":"Mantle-cell lymphoma","volume":"36","author":"Campo","year":"1999","journal-title":"Semin Hematol"},{"key":"10.1016\/j.leukres.2010.09.027_bib0020","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/cncr.23608","article-title":"Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004","volume":"113","author":"Zhou","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2010.09.027_bib0025","series-title":"World health organization classification of tumours. pathology and genetics of tumours of haematopoietic and lymphoid tissues","first-page":"189","year":"2001"},{"key":"10.1016\/j.leukres.2010.09.027_bib0030","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrc2230","article-title":"Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics","volume":"7","author":"Jares","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.leukres.2010.09.027_bib0035","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","article-title":"High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine","volume":"23","author":"Romaguera","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2010.09.027_bib0040","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"Lenz","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2010.09.027_bib0045","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1002\/cncr.11838","article-title":"Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of beta2-microglobulin and the tumor score","volume":"98","author":"Khouri","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2010.09.027_bib0050","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/07357900500283101","article-title":"Immunomodulatory drugs","volume":"23","author":"Crane","year":"2005","journal-title":"Cancer Invest"},{"key":"10.1016\/j.leukres.2010.09.027_bib0055","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood.V96.9.2943","article-title":"Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy","volume":"96","author":"Hideshima","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.09.027_bib0060","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1182\/blood.V99.12.4525","article-title":"Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications","volume":"99","author":"Mitsiades","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.09.027_bib0065","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1182\/blood.V98.1.210","article-title":"Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma","volume":"98","author":"Davies","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.09.027_bib0070","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/sj.leu.2402745","article-title":"Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo","volume":"17","author":"Lentzsch","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2010.09.027_bib0075","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1200\/JCO.2007.14.5367","article-title":"Lenalidomide for the treatment of B-cell malignancies","volume":"26","author":"Chanan-Khan","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2010.09.027_bib0080","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1182\/blood-2005-07-2817","article-title":"Combination therapy with lenalidomide plus dexamethasone (Rev\/Dex) for newly diagnosed myeloma","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.09.027_bib0085","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2010.09.027_bib0090","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2010.09.027_bib0095","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2141.2009.07626.x","article-title":"Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma","volume":"145","author":"Habermann","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2010.09.027_bib0100","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1038\/sj.leu.2403058","article-title":"Thalidomide therapy induces response in relapsed mantle cell lymphoma","volume":"17","author":"Damaj","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2010.09.027_bib0105","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.mvr.2005.01.002","article-title":"Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro","volume":"69","author":"Dredge","year":"2005","journal-title":"Microvasc Res"},{"key":"10.1016\/j.leukres.2010.09.027_bib0110","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1038\/sj.bjc.6600607","article-title":"Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects","volume":"87","author":"Dredge","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1016\/j.leukres.2010.09.027_bib0115","doi-asserted-by":"crossref","first-page":"5984","DOI":"10.1158\/1078-0432.CCR-05-0577","article-title":"Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model","volume":"11","author":"Hernandez-Ilizaliturri","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2010.09.027_bib0120","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S1470-2045(06)70723-9","article-title":"Immunomodulating drugs for chronic lymphocytic leukaemia","volume":"7","author":"Chanan-Khan","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.leukres.2010.09.027_bib0125","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.leukres.2006.01.010","article-title":"Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly","volume":"30","author":"Gandhi","year":"2006","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2010.09.027_bib0130","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1158\/0008-5472.CAN-06-2317","article-title":"Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells","volume":"67","author":"Verhelle","year":"2007","journal-title":"Cancer Res"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212610004753?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212610004753?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,13]],"date-time":"2020-06-13T13:31:13Z","timestamp":1592055073000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212610004753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["S0145212610004753"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2010.09.027","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}